Trial: Cutera Excel V versus Syneron Candela Vbeam

Written by on October 28, 2014 in clinical trials, laser therapy, pulse dye laser, V-beam with 0 Comments


Cutera, the makers of the Cutera Excel V, a 532nm KTP Laser have posted the details of trial comparing their product with the 595nm Pulse Dye Laser from Syneron Candela.

The physician and trialist will assess improvements in the blood vessels and pustules and papules of rosacea.

Additionally the trial will use a Spectrophotometer to assess changes in skin colour. Changes in the quality of life, treatment pain and adverse events will also be recorded.

The trial is to assess 20 females aged 20 to 80 in Miami, FL.

Clinical Trial NCT02268474

Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea

Sponsor: Cutera Inc.

A single center prospective, randomized, controlled split face study comparing a 532nm KTP laser with a 595nm PDL for the treatment of Erythematotelangiectatic Rosacea and Papulopustular Rosacea.

Subjects will receive up to 3 laser treatments 4 weeks apart and will be followed at 4 to 6 weeks post-final laser treatment.

Experimental: 532nm KTP Laser Cutera Excel V

Active Comparator: 595nm Pulse Dye Laser Candela/Syneron Vbeam

Device: Excel V 532nm (KTP) Laser or 595nm Pulse Dye Laser

Each subject’s face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face).

The allocation of treatment (532nm KTP laser) and active control treatment (595nm PDL) arms will be determined by randomization.

Location: Miami Dermatology & Laser Institute, Miami, Florida, United States, 33173

Related Articles

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

Leave your comment here


Discover more from Rosacea Support Group

Subscribe now to keep reading and get access to the full archive.

Continue reading

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.